A Randomised, Double-blind, Placebo-controlled, Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

Novo Nordisk A/S1 site in 1 country34 target enrollmentJanuary 2011

ConditionsInflammation Rheumatoid Arthritis

InterventionsNNC 0151-0000-0000 placebo

DrugsNNC 0151-0000-0000 placebo

Overview

Phase: Phase 2
Intervention: NNC 0151-0000-0000
Conditions: Inflammation
Sponsor: Novo Nordisk A/S
Enrollment: 34
Locations: 1
Primary Endpoint: Number of adverse events (AEs)
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability and pharmacokinetics (at which rate the drug is eliminated from the body) of NNC 151-0000-0000 in subjects with rheumatoid arthritis (RA).

Registry

clinicaltrials.gov

Start Date

January 2011

End Date

February 2013

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Novo Nordisk A/S

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•CZ: Age between 18 and 65 years (both inclusive)
•A diagnosis of rheumatoid arthritis of at least three months before entry in trial
•Active rheumatoid arthritis (RA)
•Subjects are on stable doses of methotrexate (up to and including 25 mg/week) for at least 4 weeks before trial drug administration